

Research and Reports in Gastroenterology

# **Market Analysis**

# 4th International Conference on Digestive Diseases 2020 Market Analysis

## Dr. Ahmed Hegazi

Professor, Microbiology and Immunology, National Research Center, Egypt, Email: ahmedhegazi128 @gmail.com

Market Analysis of <u>Digestive Diseases market</u> is expected to grow from USD 17.27 billion in 2016 and reach USD 19.79 billion in 2022, growing at a CAGR of 2.3% during the forecast period. Our industry experts anticipate that within the Digestive diseases market, the GIT Anti-inflammatory drug will grow at the fastest CAGR ranging from 1% to .5%, during the forecast period. Based on the geographic regions, our experts anticipate that Europe will be the fastestgrowing segment during the forecast period. The Europe region will grow at a CAGR ranking from 1% to 0.3% by 2022.

The measure of the worldwide gastrointestinal therapeutics advertise is required to reach USD 13.8 billion by 2020, quickening at a CAGR of 6.5% between 2015-2020. This development in market estimate is credited to various variables including expanding utilization of biologics, speculative endorsement generally organize particles, advancement of novel treatments utilizing imaginative innovations, and improved indicative instruments expanding the treatment-chasing populace.

Furthermore, an unexpected increment in the quantity of gastric medical procedures over the globe is legitimately affecting the development of post-careful gastroparesis cases over the globe, which will straightforwardly move development inside the gastroparesis drugs showcase throughout the following couple of years. Because of this essential development factor, the worldwide gastroparesis drugs market will build USD 940 million between 2016-2021, surpassing USD 7.1 billion in market measure before the finish of the conjecture time frame. Different elements driving the development of this market incorporate neglected needs in the business to expand the R&D in the field and the rising instances of diabetes powering the commonness of diabetic gastroparesis.

Gastrointestinal (GI) or gastroenterology is the branch of medicine related to the GI tract (stomach and intestines) and the accessory organs of digestion (from the mouth to the anus). Some of the conditions treated under this specialty include but are not limited to: Crohn's disease, gastroesophageal reflux disease (GERD), inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, colon cancer, heartburn, gastric cancer, diverticulitis, and ulcerative colitis.

While many of these illnesses are chronic and can only be treated medically, more holistic and natural approaches are being used more frequently to prevent and manage gastrointestinal disorders. Many healthcare providers are recommending stress management, a healthy diet, and exercise to prevent and manage symptoms. Exercise has shown to decrease the risk of colon cancer, minimize constipation and improve overall GI health. Even minimal exercise paired with a healthy diet of fruits, vegetables, low fat protein and avoidance of red meat, animal fat, and processed meats, can go a long way in preventing colon cancer and other GI diseases.

It is known that psychological stress can aggravate symptoms of Crohn's disease, irritable bowel syndrome, and ulcerative colitis. Taking a mind-body approach to health can help these patients manage their illnesses. Techniques such as yoga, meditation, massage, and acupuncture can lower stress and in turn reduce bowel symptoms. Doctors also recommend an anti-inflammatory diet (omega-3 fatty acids, fruits & vegetables, and protein rich food like fish, chicken and soy) for people suffering from Crohn's disease

The size of the <u>global gastrointestinal therapeutics market</u> is expected to reach USD 13.8 billion by 2020, accelerating at a CAGR of 6.5% between 2015-2020. This growth in market size is attributed to numerous factors including increasing consumption of biologics, tentative approval of late stage molecules, development of novel therapies using innovative technologies, and improved diagnostic tools increasing the treatment-seeking population.

Additionally, a sudden increase in the number of gastric surgeries across the globe is directly impacting the growth of post-surgical gastroparesis cases across the globe, which will directly propel growth within the <u>gastroparesis drugs</u> <u>market</u> over the next few years. Due to this primary growth factor, the global gastroparesis drugs market will increase USD 940 million between 2016-2021, exceeding USD 7.1 billion in market size by the end of the forecast period. Other factors driving the growth of this market include unmet needs in the industry to increase the R&D in the field and the rising cases of diabetes fueling the prevalence of diabetic gastroparesis. Other insights provided within Technavio's gastroenterology market reports include:

Gastroenterology Market Insights

• The increasing consumption of biologics for inflammatory bowel diseases (IBD) will be one of the major factors that will have a positive impact on the growth of the gastrointestinal therapeutics market size in the coming years. The emergence of biosimilars and the adoption of biosimilars as they contain active pharmaceutical ingredients that are identical to their originator biologic compounds and are also less expensive than biologics will gain traction in this market.

• The global gastroparesis drugs market will accelerate at a CAGR of 3% between 2017-2021. Fast track approvals and acquisitions to change the phase of the market and the introduction of novel ways for the treatment of gastroparesis symptoms are the emerging trends which will gain traction during the forecast period. These trends will positively impact the market's growth.

• The growing preference for minimally invasive (MI) procedures will drive the growth prospects for the <u>global</u> <u>gastrointestinal stents market</u> during the forecast period. Generally, MI surgeries have low-risk complications and other benefits such as reduced costs, shorter hospital stay, faster recovery, lesser pain, fewer post-surgery infections, reduced incision marks, bleeding control, minimal complications, and heightened accuracy.

### Gastroenterology Market Share and Segmentation

Within our gastroenterology industry research, we provide deep insights into the gastroenterology market landscape, its segments, and their market share. Our research experts segment the gastroenterology market by tract diseases and organ diseases.

- Gastrointestinal Tract Diseases Market
- o Esophagus disorders market
  - Gastroesophageal reflux disease (GERD) market
  - Eosinophilic esophagitis market
- o Stomach diseases market
  - Gastritis market
  - Gastroenteritis market
  - Gastroparesis market
  - Peptic ulcers market
- o Colonic diseases market
  - Colorectal cancer market
  - Colonic polyps' market
  - Ulcerative colitis market
- o Small Intestine disorders market
  - Celiac disease market
  - Crohn's disease market
  - Intestinal cancer market
- Gastrointestinal Organs Diseases Market
- o Liver diseases market
  - Hepatitis A market
  - Hepatitis B market
  - Hepatitis C market
  - Wilson disease market
  - Cirrhosis market


o Pancreatic diseases market

- Pancreatitis market
- Cystic fibrosis market

o Gallbladder diseases market

- Gallstone pancreatitis market
- Biliary tract disorders market

We at Technavio, with our comprehensive understanding of the gastroenterology market, have been monitoring the latest industry trends and developments to create an indepth portfolio of gastroenterology market reports. These reports help our clients identify opportunities within the market and develop effective strategies to optimize their market positions. Our gastroenterology market reports offer the following insights



### Supporting Journals

<u>Clinical Gastroenterology Journal</u>

Journal of Gastrointestinal & Digestive System Global Journal of Digestive Diseases